Prescription cannabinoids showed effectiveness for MS spasticity and pain, but herbal marijuana coverage remains unlikely
The AAN review justified insurance coverage for dronabinol and nabilone for MS spasticity and pain, but herbal marijuana remains federally illegal and uncovered by payers.
Quick Facts
What This Study Found
This commentary examined the clinical implications of the American Academy of Neurology's systematic review of cannabinoids for neurological disorders. Several cannabinoid preparations showed effectiveness or probable effectiveness for spasticity, central pain, and painful spasms in multiple sclerosis.
The authors noted that the review supports insurance coverage for prescription cannabinoids dronabinol and nabilone for MS indications, and many insurers already covered these medications for other approved uses. However, the review was unlikely to change coverage for herbal marijuana because it remains illegal under federal law.
For other neurological conditions, the available evidence was insufficient to support clinical recommendations. The commentary highlighted the gap between the scientific evidence for pharmaceutical cannabinoids and the accessibility issues created by marijuana's federal scheduling.
Key Numbers
Cannabinoids showed effectiveness or probable effectiveness for 3 MS indications: spasticity, central pain, painful spasms. Insurance coverage supported for dronabinol and nabilone. Quality evidence lacking for other neurological conditions.
How They Did This
Clinical perspectives commentary on the AAN evidence-based systematic review of randomized controlled trials of cannabis and cannabinoids in neurological disorders, with analysis of insurance and coverage implications.
Why This Research Matters
The disconnect between available pharmaceutical cannabinoids (covered by insurance) and herbal cannabis (not covered, federally illegal) creates inequity in patient access. This commentary helps clinicians understand what they can practically prescribe and what insurance will cover.
The Bigger Picture
The medical cannabis landscape involves a tension between pharmaceutical cannabinoids (regulated, studied, insurable) and herbal marijuana (unregulated, variably studied, uninsurable). This commentary makes the practical implications clear for both clinicians and patients.
What This Study Doesn't Tell Us
Commentary based on a single systematic review. Coverage policies vary by insurer and jurisdiction. The distinction between pharmaceutical and herbal cannabis may oversimplify the therapeutic landscape. Published before many states expanded medical programs.
Questions This Raises
- ?Has federal rescheduling affected coverage since 2015?
- ?Do patients respond differently to pharmaceutical vs. herbal cannabinoids for MS?
- ?Would standardized herbal cannabis preparations become insurable?
Trust & Context
- Key Stat:
- Dronabinol and nabilone: insurance coverage justified for MS indications
- Evidence Grade:
- Clinical commentary based on the AAN systematic review of randomized controlled trials.
- Study Age:
- Published in 2015. Cannabis scheduling and insurance policies have evolved since.
- Original Title:
- Clinical perspectives on medical marijuana (cannabis) for neurologic disorders.
- Published In:
- Neurology. Clinical practice, 5(4), 344-351 (2015)
- Database ID:
- RTHC-00956
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Will insurance cover cannabis for neurological conditions?
As of this 2015 commentary, prescription cannabinoids (dronabinol, nabilone) could be covered for MS spasticity and pain. Herbal marijuana was not covered due to federal illegality. Current coverage may differ.
Which neurological conditions have evidence for cannabis?
The strongest evidence was for MS spasticity, central pain, and painful spasms. For other neurological conditions, the AAN found quality scientific evidence lacking at the time.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00956APA
Fife, Terry D; Moawad, Heidi; Moschonas, Constantine; Shepard, Katie; Hammond, Nancy. (2015). Clinical perspectives on medical marijuana (cannabis) for neurologic disorders.. Neurology. Clinical practice, 5(4), 344-351.
MLA
Fife, Terry D, et al. "Clinical perspectives on medical marijuana (cannabis) for neurologic disorders.." Neurology. Clinical practice, 2015.
RethinkTHC
RethinkTHC Research Database. "Clinical perspectives on medical marijuana (cannabis) for ne..." RTHC-00956. Retrieved from https://rethinkthc.com/research/fife-2015-clinical-perspectives-on-medical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.